Edwards Lifesciences Co. (NYSE:EW) CEO Acquires $49,729.20 in Stock

Edwards Lifesciences Co. (NYSE:EW) CEO Bernard J. Zovighian bought 580 shares of the stock in a transaction dated Monday, May 6th. The shares were acquired at an average price of $85.74 per share, for a total transaction of $49,729.20. Following the completion of the purchase, the chief executive officer now directly owns 3,268 shares in the company, valued at $280,198.32. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.

Edwards Lifesciences Stock Performance

NYSE EW opened at $87.42 on Friday. The company’s 50 day simple moving average is $90.03 and its two-hundred day simple moving average is $79.73. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. Edwards Lifesciences Co. has a 1 year low of $60.57 and a 1 year high of $96.12. The stock has a market capitalization of $52.68 billion, a PE ratio of 37.68, a P/E/G ratio of 3.59 and a beta of 1.10.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.58 billion. Analysts predict that Edwards Lifesciences Co. will post 2.77 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. DSM Capital Partners LLC bought a new stake in Edwards Lifesciences during the fourth quarter valued at approximately $28,000. Turtle Creek Wealth Advisors LLC purchased a new stake in shares of Edwards Lifesciences during the 4th quarter valued at $34,000. Riverview Trust Co bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $34,000. Pingora Partners LLC purchased a new position in Edwards Lifesciences in the fourth quarter worth $38,000. Finally, Operose Advisors LLC increased its stake in Edwards Lifesciences by 247.0% in the third quarter. Operose Advisors LLC now owns 635 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 452 shares during the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. OTR Global raised shares of Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. StockNews.com upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a research note on Monday, April 29th. Piper Sandler raised their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the stock a “neutral” rating in a research report on Friday, April 26th. Barclays upped their price target on Edwards Lifesciences from $100.00 to $101.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Citigroup lifted their price objective on Edwards Lifesciences from $90.00 to $98.00 and gave the stock a “neutral” rating in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, six have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $93.27.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.